Diagnosis of psychiatric disorders currently depends on clinical criteria. In the future the hope is that identification of appropriate biomarkers will enable earlier diagnosis and earlier treatment to improve outcomes for patients. This is particularly critical for schizophrenia to reduce illness severity and improve its course. At EPA2019, the latest research on identifying potential biomarkers in psychiatry was presented in a fascinating state-of-the-art symposium to a packed audience of psychiatrists.

For the latest updates on sea.progress.im, subscribe to our Telegram Channel https://bit.ly/telePiM